Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys: Hold Rating Amid Mixed Financial Signals and Uncertainty Post-Merger Announcement
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Siemens Healthineers AG (OtherSEMHF) and Penumbra (PEN)
William Blair Maintains Amedisys(AMED.US) With Hold Rating
William Blair Sticks to Its Hold Rating for Amedisys (AMED)
RBC Capital Maintains Amedisys(AMED.US) With Buy Rating, Maintains Target Price $100
RBC Capital Reiterates Outperform on Amedisys, Maintains $100 Price Target
Cantor Fitzgerald Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Raymond James Maintains Amedisys(AMED.US) With Hold Rating
Amedisys Price Target Maintained With a $101.00/Share by Stephens & Co.
Amedisys Analyst Ratings
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys Hold Rating: Mixed Performance and Cost Pressures Amid Regulatory Uncertainties
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
William Blair Maintains Amedisys(AMED.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Amedisys (AMED) and CSPC Pharmaceutical Group (OtherCHJTF)
William Blair Reaffirms Their Hold Rating on Amedisys (AMED)
Amedisys Price Target Maintained With a $101.00/Share by Stephens & Co.